AveXis - Deerfield, IL 3.8

AveXis is advancing cutting-edge science, starting with our proprietary gene therapy for the treatment of spinal muscular atrophy (SMA).

Estimated: $63,000 - $87,000 a year

AveXis - Bannockburn, IL 3.8

AveXis is advancing cutting-edge science, starting with our proprietary gene therapy for the treatment of spinal muscular atrophy (SMA).

Estimated: $140,000 - $190,000 a year

AveXis - Bannockburn, IL 3.8

AveXis is advancing cutting-edge science, starting with our proprietary gene therapy for the treatment of spinal muscular atrophy (SMA).

Estimated: $85,000 - $110,000 a year

AveXis - Bannockburn, IL 3.8

AveXis is seeking a Manager, Clinical Documentation to oversee the day-to-day operations of trial master file (TMF) management.

Estimated: $66,000 - $91,000 a year

AveXis - Bannockburn, IL 3.8

AveXis is advancing cutting-edge science, starting with our proprietary gene therapy for the treatment of spinal muscular atrophy (SMA).

Estimated: $130,000 - $170,000 a year

AveXis - Bannockburn, IL 3.8

AveXis is advancing cutting-edge science, starting with our proprietary gene therapy for the treatment of spinal muscular atrophy (SMA).

Estimated: $67,000 - $98,000 a year

AveXis - Bannockburn, IL 3.8

AveXis is advancing cutting-edge science, starting with our proprietary gene therapy for the treatment of spinal muscular atrophy (SMA).

Estimated: $75,000 - $100,000 a year

AveXis - Bannockburn, IL 3.8

AveXis is advancing cutting-edge science, starting with our proprietary gene therapy for the treatment of spinal muscular atrophy (SMA).

Estimated: $130,000 - $170,000 a year

AveXis - Bannockburn, IL 3.8

AveXis is advancing cutting-edge science, starting with our proprietary gene therapy for the treatment of spinal muscular atrophy (SMA).

Estimated: $88,000 - $110,000 a year